Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation
Status:
Completed
Trial end date:
2019-06-15
Target enrollment:
Participant gender:
Summary
Tocilizumab will be administered prior to transplantation in order to prevent the onset of
cytokine release syndrome and its complications associated to peripheral blood haploidentical
hematopoietic stem cell transplantation with post-transplant cyclophosphamide